

Theories about the roles of KD

1. Glucose metabolism produces rapidly available energy that is necessary for seizure activity. In patients on KD, blood glucose energy level is low, and the brain begins to use ketone bodies for energy. This anaerobic metabolism slows the energy availability, which reduces seizures.³
2. Chronic ketosis elevates the brain's energy reserve through stabilization and reduction of synapses excitability.⁴ There was an increase in mitochondria production in an experimental model of rats fed with KD, indicating an increase in energy stores.⁵ This leads to an increase in ATP production, which activates KATP, eventually reduces neuronal excitability.
3. KD interferes with the concentration of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter. In clinical practice, there is an increased GABA levels in the CSF of patients on the KD diet.⁶ The decrease in aspartate levels promoted by KB leads to the synthesis of GABA.⁷
4. KD modifies the gut microbiota, causing an increase in the reputedly beneficial bacteria *Akkermansia muciniphila* and *Parabacteroides* spp. This leads to a decrease in gamma-glutamyl amino acids. The decreasing level of gamma-glutamyl amino acids in the blood increases the GABA/glutamate content in the brain.⁸

Paediatric patients are usually prescribed syrups or suspensions, which often contain sucrose to improve palatability. For paediatric patients on a ketogenic diet, the pharmacists should suggest alternative medications that could be crushed and are stable when diluted in water or other non-sucrose vehicles.

In conclusion, the mechanisms described can lead to changes in the seizure threshold and hyperexcitability, contributing to the final antiseizure mechanism of KD. Pharmacists play an important role in the optimal management of EE patients with KD.

References:

1. Lennox Gastaut Syndrome Information, National Institute of Neurological Disease and Stroke, taken from <https://www.ninds.nih.gov/disorders/all-disorders/lennox-gastaut-syndrome-information-page>, January 2022.
2. Rho, J. M., Anderson, G. D., Donevan, S. D., and White, H. S. (2002). Acetoacetate, acetone, and dibenzylamine (a contaminant in L-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. *Epilepsia* 43, 358–361. doi: 10.1046/j.1528-1157.2002.47901.x
3. Greene, A. E., Todorova, M. T., and Seyfried, T. N. (2003). Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. *J. Neurochem.* 86, 529–537. doi: 10.1046/j.1471-4159.2003.01862.x
4. Bough, K. (2008). Energy metabolism as part of the anticonvulsant mechanism of the ketogenic diet. *Epilepsia* 49(Suppl. 8), 91–93. doi: 10.1111/j.1528-1167.2008.01846.x
5. Wang, Z. J., Bergqvist, C., Hunter, J. V., Jin, D., Wang, D.-J., Wehrli, S., et al. (2003). In vivo measurement of brain metabolites using twodimensional double-quantum MR spectroscopy? exploration of GABA levels in a ketogenic diet. *Magn. Reson. Med.* 49, 615–619. doi: 10.1002/mrm.10429
6. Yudkoff, M., Daikhin, Y., Horyn, O., Nissim, I., and Nissim, I. (2008). Ketosis and brain handling of glutamate, glutamine, and GABA. *Epilepsia* 49, 73–75. doi: 10.1111/j.1528-1167.2008.01841.x
7. Olson, C. A., Vuong, H. E., Yano, J. M., Liang, Q. Y., Nusbaum, D. J., and Hsiao, E. Y. (2018). The gut microbiota mediates the anti-seizure effects of the ketogenic diet. *Cell* 173, 1728–1741.e13. doi: 10.1016/j.cell.2018.04.027
8. Kim, D. Y., Simeone, K. A., Simeone, T. A., Pandya, J. D., Wilke, J. C., Ahn, Y., et al. (2015). Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. *Ann. Neurol.* 78, 77–87. doi: 10.1002/ana.24424